--(www.USEquityNews.com)-- 06/05/2008 - Healthcare industry alert provided by U.S. Equity News. Seattle Genetics, Inc. (NASDAQ: SGEN) today announced final data from the phase I clinical trial of SGN-40 in patients with relapsed or refractory non-Hodgkin lymphoma. SGN-40 is a humanized monoclonal antibody being developed under a worldwide collaboration agreement with Genentech, Inc. Multiple objective responses were achieved and SGN-40 was generally well tolerated with no maximum tolerated dose identified. The data were reported during an oral presentation at the International Conference on Malignant Lymphoma (ICML) being held in Lugano, Switzerland. "These data are encouraging considering that patients treated on this phase I clinical trial were heavily pretreated and had limited therapeutic options," said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics.
ViroPharma Incorporated (NASDAQ: VPHM) notes that FDA has published a notice of a meeting of its Advisory Committee for Pharmaceutical Science and Clinical Pharmacology to be held on July 23, 2008. For over two years, ViroPharma has called for a deliberative public discussion that would include input from clinicians as well as biopharmaceutics and dissolution experts. Bioequivalence determinations for locally acting GI drugs, particularly drugs like Vancocin(R) that treat a serious and potentially life threatening disease, are complex. Clostridium difficile infection results in significant morbidity and mortality, and has developed into a national health issue. The risk to patients of a product that is not bioequivalent to Vancocin in this setting is high.
TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma. The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition. For more information, please visit www.stocksjournal.com.
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that Alan Musso, Vice President and Chief Financial Officer, is scheduled to present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference at The New York Palace Hotel, on Thursday, June 12, 2008 at 2:30 p.m. Eastern Daylight Time. Mr. Musso's presentation will be webcast and accessible from the Investor Relations section of Targacept's website, www.targacept.com. The webcast will also be available for replay for at least two weeks following the presentation.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
